The Biden administration's recent decision has significant implications for individuals reliant on the GLP-1 medication tirzepatide. By declaring an end to the medication's shortage, the administration has inadvertently set the stage for increased drug prices, as lower-cost compounded alternatives will be removed from the market on March 19. Many patients currently paying $350 monthly could subsequently face costs exceeding $1,000 for name-brand versions, which insurance often doesn't cover. This decision could severely impact millions who have come to depend on these medications for health management and weight loss.
Ending a shortage sounds like a good thing, so how exactly can this decision harm Americans? First, understand that Biden's unilateral decree did nothing to change reality.
Without government acknowledgment of that fact, pharmacies will no longer be permitted to sell alternative, lower-cost compounded versions of the medication - and costs to consumers will soar.
Simply put, tirzepatide will become unaffordable overnight for many who rely on it. GLP-1 medications like tirzepatide have become a cornerstone of health management for millions of Americans.
Patients who today can get the drug compounded for $350 a month will have no option but to pay $1,000 a month for Mounjaro or Zepbound.
Collection
[
|
...
]